The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2016 Release

August 26, 2016ANTICANCER AGENT “TREAKISYM® FOR INJECTION 100 MG” APPROVED IN JAPAN FOR ADDITIONAL INDICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA
August 23, 2016EISAI TO LAUNCH CHOCOLA BB® MOUTH ULCER REPAIR SHOT
FIRST MOUTH ULCER SPRAY FOR THE CHOCOLA BB BRAND
August 9, 2016U.S. FDA CONFIRMS SUFFICIENT DATA TO ADVANCE INVESTIGATIONAL BACE INHIBITOR E2609 FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE TO PHASE III
PLANNING UNDERWAY TOWARDS PHASE III STUDY INITIATION IN FY2016
August 5, 2016CHINA FOOD AND DRUG ADMINISTRATION ACCEPTS NDA FOR ANTICANCER AGENT HALAVEN®
August 3, 2016CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
August 1, 2016EISAI AND MAMORIO TO JOINTLY DEVELOP “ME-MAMORIO” TRACKING TOOL TO SUPPORT PEOPLE WITH DEMENTIA GOING OUT
August 1, 2016EISAI PRESENTS RESULTS OF ADDITIONAL ANALYSIS OF PHASE III STUDY OF ANTICANCER AGENT HALAVEN® AT 14TH JSMO ANNUAL MEETING PLENARY SESSION
July 27, 2016 Notification Regarding Revision of Consolidated Financial Forecasts (IFRS)
July 22, 2016 EISAI RECEIVES POSITIVE CHMP OPINION ON NEW INDICATION FOR ANTICANCER AGENT LENVATINIB IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF ADVANCED RENAL CELL CARCINOMA
July 19, 2016 U.S. FDA APPROVES BELVIQ XR®, A ONCE-DAILY FORMULATION OF LORCASERIN FOR CHRONIC WEIGHT MANAGEMENT
July 14, 2016 ANTIOBESITY AGENT VENESPRI® (LORCASERIN) APPROVED IN MEXICO
FIRST COUNTRY IN LATIN AMERICA TO APPROVE LORCASERIN
July 13, 2016 Correction to “Notification Regarding the Continuation and Partial Revision of the Performance-Related Stock Compensation System”
July 11, 2016 NTT IT, NTT East and Eisai Rollout Interprofessional Collaboration Business for Medical Treatment and Care
July 4, 2016 EISAI LAUNCHES IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA® IN MEXICO
June 30, 2016 EISAI LISTED FOR 15TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
June 27, 2016 Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
June 20, 2016 AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF-α Monoclonal Antibody Humira® in Patients with Crohn's Disease
June 16, 2016 Notice Regarding the Recording of One-time Income in Association with Acquisition of EA Pharma Shares
June 16, 2016 EISAI LAUNCHES NEW ORAL SUSPENSION FORMULATION FOR ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL) IN THE UNITED STATES
As Adjunctive Therapy for the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures in Patients with Epilepsy
June 13, 2016 EISAI PRESENTS LATEST PHASE I/II DATA ON IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011
RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITY IN RHEUMATOID ARTHRITIS AND CROHN'S DISEASE
June 3, 2016 EISAI INC. ENTERS INTO COLLABORATION AGREEMENT TO CO-PROMOTE EISAI'S ANTICANCER AGENT LENVIMA® IN COMBINATION WITH EVEROLIMUS AS TREATMENT FOR ADVANCED RENAL CELL CARCINOMA IN THE UNITED STATES
June 1, 2016 ANTICANCER AGENT HALAVEN® APPROVED IN THE PHILIPPINES FOR NEW INDICATION FOR TREATMENT OF SOFT TISSUE SARCOMA
SECOND COUNTRY IN ASIA AFTER JAPAN TO APPROVE HALAVEN FOR SOFT TISSUE SARCOMA
June 1, 2016 AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® in the Field of Gastrointestinal Disease
May 31, 2016 Notification Regarding the Completion of the Disposal of Treasury Stock Through Third-Party Allotment in Accordance with the Continuation of Performance-Related Stock Compensation System
May 25, 2016 EISAI TO LAUNCH IN-HOUSE DEVELOPED ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL HYDRATE) AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES IN JAPAN
May 24, 2016 EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 52ND ASCO ANNUAL MEETING
May 16, 2016 U.S. FDA APPROVES ADDITIONAL INDICATION FOR EISAI’S ANTICANCER AGENT LENVIMA® IN COMBINATION WITH EVEROLIMUS AS TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
May 13, 2016 ANTICANCER AGENT HALAVEN® DEMONSTRATES STATISTICALLY SIGNIFICANT EXTENSION IN PROGRESSION FREE SURVIVAL COMPARED TO VINORELBINE IN PHASE III CLINICAL STUDY OF PATIENTS WITH BREAST CANCER IN CHINA
May 13, 2016 Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of Performance-Related Stock Compensation System
May 13, 2016 Notification Regarding the Continuation and Partial Revision of the Performance-Related Stock Compensation System
May 6, 2016 EISAI RECEIVES APPROVAL FOR NEW INDICATION FOR ANTICANCER AGENT HALAVEN® FOR TREATMENT OF ADVANCED LIPOSARCOMA IN EUROPE
April 26, 2016 CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
April 20, 2016 EISAI TO SUPPORT RELIEF EFFORTS FOR 2016 KUMAMOTO EARTHQUAKES
April 20, 2016 EISAI ANNOUNCES NON-CLINICAL RESEARCH FINDINGS AT AACR 107TH ANNUAL MEETING REGARDING COMBINATION OF ANTICANCER AGENT LENVATINIB WITH EVEROLIMUS
ENHANCED MECHANISM OF ANGIOGENESIS INHIBITION AND ANTI-TUMOR ACTIVITY IN RENAL CELL CARCINOMA INVESTIGATED
April 14, 2016 ARICEPT® APPROVED IN THE PHILIPPINES FOR NEW INDICATION AS TREATMENT FOR DEMENTIA WITH LEWY BODIES
SECOND COUNTRY IN THE WORLD AFTER JAPAN TO APPROVE ARICEPT FOR DEMENTIA WITH LEWY BODIES
April 5, 2016 EISAI RECEIVES POSITIVE CHMP OPINION ON NEW INDICATION FOR ANTICANCER AGENT HALAVEN® FOR TREATMENT OF ADVANCED LIPOSARCOMA
March 31, 2016 EISAI TRANSFERS THE RIGHTS TO INVESTIGATIONAL ANTICANCER AGENT E7777 FOR EUROPEAN, U.S. AND CERTAIN EMERGING MARKETS TO DR. REDDY'S LABORATORIES
March 30, 2016 EISAI CO., LTD. AND AJINOMOTO CO., INC. ANNOUNCE ESTABLISHMENT OF GASTROINTESTINAL SPECIALTY PHARMA EA PHARMA CO., LTD. THROUGH THE INTEGRATION OF EISAI'S GASTROINTESTINAL DISEASE BUSINESS AND AJINOMOTO PHARMACEUTICALS CO., LTD.
March 30, 2016 Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
March 30, 2016 EISAI'S U.S. SUBSIDIARY EISAI INC. ENTERS SHARE PURCHASE AGREEMENT CONCERNING AKARX INC. IN THE U.S.
RIGHTS TO IN-HOUSE DEVELOPED THROMBOCYTOPENIA TREATMENT AVATROMBOPAG TO BE TRANSFERRED
March 30, 2016 Notice Concerning Shelf Registration for Issuance of Stock Options
March 28, 2016 EISAI'S IN-HOUSE DEVELOPED ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL HYDRATE) APPROVED IN JAPAN AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES
March 22, 2016 EISAI WITHDRAWS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRA-HIGH DOSE PREPARATION AS TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS
March 22, 2016 JOINT PROMOTION AGREEMENT ON ANTIEMETIC AGENT WITH HELSINN THERAPEUTICS INC. IN THE UNITED STATES REVISED
Eisai to Return All Rights to Promote and Distribute AKYNZEO® (netupitant/palonosetron) to Helsinn Therapeutics Inc.
March 17, 2016 NOTICE REGARDING DISCONTINUATION OF SALES AND VOLUNTARY RECALL OF EGG WHITE LYSOZYME PREPARATION NEUZYM®
March 1, 2016 Notification Regarding Change in Representative Corporate Officers
February 29, 2016 EISAI'S ANTICANCER AGENT HALAVEN® NEWLY APPROVED IN JAPAN FOR TREATMENT OF SOFT TISSUE SARCOMA
February 29, 2016 AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA®, a Fully Human Anti-TNF-α Monoclonal Antibody, in the Treatment of Polyarticular Juvenile Idiopathic Arthritis
February 15, 2016 EISAI AND SYSMEX ENTER COMPREHENSIVE AGREEMENT TO CREATE NEXT-GENERATION DIAGNOSTIC REAGENTS IN THE FIELD OF DEMENTIA
February 12, 2016 PHASE III TRIAL RESULTS OF EISAI'S ANTICANCER AGENT HALAVEN® IN SOFT TISSUE SARCOMA PUBLISHED IN THE LANCET
February 2, 2016 Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
February 1, 2016 EISAI ACQUIRES EXCLUSIVE LICENSE FROM HUYA BIOSCIENCE INTERNATIONAL TO DEVELOP AND MARKET HDAC INHIBITOR HBI-8000 IN JAPAN AND OTHER ASIAN COUNTRIES
January 29, 2016 U.S. FDA APPROVES EISAI’S ANTICANCER AGENT HALAVEN® FOR THE TREATMENT OF ADVANCED LIPOSARCOMA
January 18, 2016 U.S. FDA ACCEPTS FOR PRIORITY REVIEW sNDA FOR EISAI’S ANTICANCER AGENT LENVATINIB SEEKING APPROVAL FOR RENAL CELL CARCINOMA
January 12, 2016 EISAI SUBMITS NEW APPLICATION IN EUROPE FOR IN-HOUSE DEVELOPED ANTICANCER AGENT LENVATINIB SEEKING APPROVAL FOR INDICATION COVERING RENAL CELL CARCINOMA
APPLICATION BASED ON RESULTS OF PHASE II CLINICAL STUDY

Back to Top

2015 Release

December 28, 2015 EISAI COMPLETES ACQUISITION OF CHINESE GENERIC PHARMACEUTICAL COMPANY LIAONING TIANYI BIOLOGICAL PHARMACEUTICAL CO., LTD.
December 18, 2015 Notice Regarding Succession of Business of Consolidated Pharmaceutical Manufacturing and Marketing Subsidiary Sannova
December 11, 2015 MHLW APPROVES PARTIAL LABEL CHANGE FOR EGG-WHITE LYSOZYME PREPARATION NEUZYM®
December 2, 2015 EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) AT 69TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
December 1, 2015 EISAI AND TOYAMA CHEMICAL CLEAR ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTIRHEUMATIC AGENT IGURATIMOD
(BRAND NAMES: CARERAM® TABLETS 25 MG/KOLBET® TABLETS 25 MG)
December 1, 2015 U.S. FDA ACCEPTS NDA FOR ONCE-DAILY FORMULATION OF ANTIOBESITY AGENT BELVIQ®
November 27, 2015 EISAI TO ACQUIRE CHINESE GENERIC PHARMACEUTICAL COMPANY LIAONING TIANYI BIOLOGICAL PHARMACEUTICAL CO., LTD.
STRENGTHENING BUSINESS PLATFORM IN CHINA TO ADDRESS DIVERSE MEDICAL NEEDS
November 26, 2015 Notice Regarding Transfer of Shares in Eisai Subsidiary
November 20, 2015 Notice Regarding Transfer of Shares Involving Changes in Eisai Subsidiary
November 20, 2015 EISAI LICENSES SELECTIVE PHOSPHODIESTERASE 4 INHIBITOR E6005 TO ROIVANT SCIENCES
November 17, 2015 SUCCESSFUL RULING IN PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI® IN THE UNITED STATES
November 5, 2015 EISAI TO COMMENCE TWO JOINT RESEARCH PROGRAMS TOWARD DEVELOPMENT OF NEW ANTIMALARIAL MEDICINES
PARTNERSHIPS WITH LIVERPOOL SCHOOL OF TROPICAL MEDICINE / UNIVERSITY OF LIVERPOOL AND MEDICINES FOR MALARIA VENTURE
November 2, 2015 EISAI PRESENTS RESULTS FROM PHASE III TRIAL OF ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL-ONSET SEIZURES CONDUCTED IN ASIA INCLUDING JAPAN
ORAL PRESENTATION GIVEN AT 49TH CONGRESS OF THE JAPAN EPILEPSY SOCIETY
October 19, 2015 PHASE II TRIAL RESULTS ON NOVEL ANTICANCER AGENT LENVIMA® IN RENAL CELL CARCINOMA PUBLISHED IN THE LANCET ONCOLOGY
October 15, 2015 AGREEMENT CONCERNING THE INTEGRATION OF THE GASTROINTESTINAL DISEASE BUSINESS OF EISAI CO., LTD. AND AJINOMOTO PHARMACEUTICALS CO., LTD. BY ABSORPTION-TYPE SPLIT
Aiming to become Japan's Largest Gastrointestinal Specialty Pharma
October 9, 2015 EISAI RECEIVES APPROVAL FOR ANTICANCER AGENT LENVIMA® IN SOUTH KOREA
October 5, 2015 EISAI TO PROVIDE DIETHYLCARBAMAZINE CITRATE TABLETS FREE OF CHARGE FOR USE IN NATIONAL LYMPHATIC FILARIASIS ELIMINATION CAMPAIGN IN INDONESIA
September 30, 2015 Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
September 29, 2015 EISAI RECEIVES ADDITIONAL APPROVAL IN JAPAN FOR VASCULAR EMBOLIZATION DEVICE DC BEAD® AS TREATMENT OF HYPERVASCULAR TUMORS AND ARTERIOVENOUS MALFORMATIONS
To be Applicable for Insurance Reimbursement Once Listing Procedures are Completed
September 29, 2015 U.S. FDA GRANTS PRIORITY REVIEW STATUS TO sNDA FOR ANTICANCER AGENT HALAVEN® AS TREATMENT FOR SOFT TISSUE SARCOMA
September 25, 2015 EISAI TO SPONSOR LECTURES AT JAPAN RESEARCH CENTER OF FUDAN UNIVERSITY IN CHINA
TO PROMOTE FURTHER UNDERSTANDING BETWEEN CHINA AND JAPAN AS WELL AS ADVANCE CULTURAL EXCHANGE
September 17, 2015 EISAI SELECTED FOR THIRD CONSECUTIVE YEAR OF MEMBERSHIP OF DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2015
September 14, 2015 EISAI TO PRESENT LATEST CLINICAL DATA ON LENVIMA® (LENVATINIB) AND HALAVEN® (ERIBULIN) AT EUROPEAN CANCER CONGRESS
September 10, 2015 Drugs for Neglected Diseases initiative and Eisai Co., Ltd. to Test Drug Candidate for Eumycetoma
Patients suffering from virtually no R&D for this neglected disease
September 10, 2015 LAUNCH OF NEW KL-6 DIAGNOSTIC KIT HISCL KL-6, FOR DETECTING MARKER FOR INTERSTITIAL PNEUMONIA WITH HISCL AUTOMATED IMMUNOASSAY SYSTEMS
September 2, 2015 EISAI CLEARS ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTICANCER DRUG GLIADEL® 7.7MG IMPLANT
August 31, 2015 EISAI INC. AND PURDUE PHARMA ENTER WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE LEMBOREXANT
Companies to develop lemborexant for the potential treatment of insomnia and explore other future indications
August 5, 2015 EISAI LISTED FOR 14TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
July 31, 2015 EISAI AND HALOZYME SIGN COLLABORATION AGREEMENT TO INVESTIGATE ERIBULIN AND PEGPH20 IN ADVANCED BREAST CANCER
July 31, 2015 CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
July 30, 2015 EISAI SUBMITS APPLICATIONS FOR ANTICANCER AGENT HALAVEN® SIMULTANEOUSLY IN JAPAN, U.S. AND EUROPE SEEKING NEW INDICATION AS TREATMENT FOR SOFT TISSUE SARCOMA
July 29, 2015 EISAI'S IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA® RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM U.S. FDA FOR RENAL CELL CARCINOMA
July 27, 2015 EISAI SUBMITS NEW DRUG APPLICATION IN JAPAN FOR IN-HOUSE-DISCOVERED ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES
July 21, 2015 JCR AND EISAI CONCLUDE FEASIBILITY STUDY AGREEMENT ON APPLICATION OF BLOOD-BRAIN-BARRIER PENETRATION TECHNOLOGY TO DISCOVER NEW TREATMENTS
July 16, 2015 EISAI ENTERS AGREEMENT TO TRANSFER NORTH CAROLINA PLANT IN THE U.S. TO BIOGEN
July 15, 2015 LAUNCH OF STACIA CLEIA PIVKA-II EISAI DIAGNOSTIC KIT FOR DETECTING HEPATOCELLULAR CARCINOMA TUMOR MARKER WITH AUTOMATED IMMUNOANALYZER
June 26, 2015 EISAI TO LAUNCH NEW FINE GRANULE FORMULATION OF TACHYARRHYTHMIA TREATMENT TAMBOCOR® SUITABLE FOR PEDIATRIC PATIENTS IN JAPAN
June 25, 2015 EUROPEAN COMMISSION APPROVES INDICATION EXPANSION OF EISAI’S ANTIEPILEPTIC AGENT FYCOMPA® FOR ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 22, 2015 U.S. FDA APPROVES EISAI’S ANTIEPILEPTIC AGENT FYCOMPA® AS ADJUNCTIVE TREATMENT FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 10, 2015 EISAI LAUNCHES ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) IN UNITED KINGDOM INDICATED FOR ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
June 1, 2015 PHASE II TRIAL RESULTS ON ANTICANCER AGENT LENVIMA® IN RENAL CELL CARCINOMA TO BE DETAILED IN ORAL PRESENTATION AT 51ST ASCO ANNUAL MEETING
COMBINATION THERAPY WITH EVEROLIMUS DEMONSTRATES SIGNIFICANT EXTENSION IN PROGRESSION-FREE SURVIVAL
June 1, 2015 EISAI RECEIVES EUROPEAN COMMISSION APPROVAL OF ANTICANCER AGENT LENVIMA® FOR TREATMENT OF ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
May 30, 2015 ANTICANCER AGENT HALAVEN® SHOWS SIGNIFICANT EXTENSION IN OVERALL SURVIVAL IN PHASE III STUDY ON SOFT TISSUE SARCOMA
Phase III data to be presented in a Soft Tissue Sarcoma oral session at ASCO
May 29, 2015 EISAI SUBMITS APPLICATIONS FOR REEVALUATION OF EFFICACY AND PARTIAL CHANGE TO LABEL OF EGG WHITE LYSOZYME PREPARATION NEUZYM® BASED ON RESULTS OF REEVALUATION STUDIES
May 29, 2015 AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA®, a Fully Human Anti-TNF-α Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis
May 27, 2015 EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRA-HIGH DOSE PREPARATION AS TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN
May 27, 2015 EISAI RECEIVES POSITIVE CHMP OPINION ON INDICATION EXPANSION FOR ANTIEPILEPTIC AGENT FYCOMPA® (PERAMPANEL) AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
May 21, 2015 EISAI TO PROMOTE CLINICAL TRIAL DATA DISCLOSURE FOR THE ADVANCEMENT OF SCIENCE AND MEDICINE
May 20, 2015 EISAI LAUNCHES IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE THYROID CANCER IN JAPAN
May 14, 2015 Notification Regarding Partial Amendment to the Articles of Incorporation
May 14, 2015 EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 51ST ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW CLINICAL DATA ON HALAVEN® (ERIBULIN) IN SOFT TISSUE SARCOMA AND ON LENVIMA® (LENVATINIB) IN RENAL CELL CARCINOMA
April 27, 2015 EISAI AND NIHON MEDI-PHYSICS ENTER COLLABORATION AGREEMENT TO CONTRIBUTE TO DIAGNOSIS AND TREATMENT OF DEMENTIA WITH LEWY BODIES
April 24, 2015 EISAI COMMENCES BUSINESS IN MEXICO, AIMS TO EXPAND CONTRIBUTION TO PATIENTS IN LATIN AMERICA
ANTICANCER AGENTS HALAVEN® AND GLIADEL® NEWLY LAUNCHED
April 13, 2015 EISAI AND GENOMICS PLC TO COLLABORATE IN ANALYSES OF LARGE-SCALE GENOTYPE/PHENOTYPE DATA TO INFORM DRUG DEVELOPMENT
April 3, 2015 NIIGATA UNIVERSITY AND EISAI PRESENT RESULTS OF JOINT RESEARCH IN U.S. ACADEMIC JOURNAL
MEASURING COGNITIVE DECLINE IN PATIENTS WITH ALZHEIMER'S DISEASE USING BLOOD-BASED BIOMARKERS
March 30, 2015 EISAI RECEIVES POSITIVE OPINION FROM EMA'S CHMP ON ANTICANCER AGENT LENVIMA® FOR TREATMENT OF ADVANCED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE
CHMP Opinion Based on Positive SELECT Study Data
March 26, 2015 EISAI RECEIVES APPROVAL IN JAPAN FOR ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE THYROID CANCER
March 12, 2015 STATEMENT REGARDING CHANGES TO STRATEGIC PARTNERSHIP WITH EPIZYME, INC. TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTICANCER THERAPIES TARGETING EZH2 EPIGENETIC ENZYME
March 5, 2015 Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored
March 3, 2015 CHINA JSFDA ACCEPTS EISAI'S APPLICATION SEEKING ADDITIONAL INDICATION OF SEVERE ALZHEIMER'S DISEASE FOR ARICEPT®
March 2, 2015 EISAI LAUNCHES ANTICANCER AGENT LENVIMA™ IN THE UNITED STATES
FIRST COUNTRY IN THE WORLD TO GAIN ACCESS TO NEW TREATMENT OPTION
February 25, 2015 EISAI TO ESTABLISH ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
February 25, 2015 PHASE III TRIAL OF ANTICANCER AGENT HALAVEN® IN SOFT TISSUE SARCOMA SHOWS OVERALL SURVIVAL BENEFIT IN PRIMARY ENDPOINT
February 24, 2015 ADDITIONAL EXPLORATORY ANALYSIS OF PHASE II TRIAL SUGGESTS ANTICANCER AGENT LENVATINIB EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
February 24, 2015 EISAI LAUNCHES PROTON PUMP INHIBITOR PARIET® TABLETS 5 MG IN JAPAN
February 19, 2015 EISAI RECEIVES APPROVAL IN JAPAN FOR FINE GRANULE FORMULATION OF ANTI-ARRHYTHMIC AGENT TAMBOCOR® SUITABLE FOR PEDIATRIC PATIENTS
February 16, 2015 U.S. FDA APPROVES ANTICANCER AGENT LENVIMA™ (LENVATINIB MESYLATE) AS TREATMENT FOR RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 16, 2015 EISAI RECEIVES APPROVAL OF ANTIEPILEPTIC DRUG BANZEL® (RUFINAMIDE) AS ADJUNCTIVE TREATMENT FOR PEDIATRIC PATIENTS IN THE UNITED STATES
U.S. PATENT EXCLUSIVITY EXTENDED BY SIX MONTHS
February 12, 2015 ANTICANCER AGENT LENVATINIB PHASE III TRIAL RESULTS PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE
SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL SHOWN IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 5, 2015 NOTICE REGARDING EISAI'S OPTIONS RELATING TO BIOGEN IDEC'S INVESTIGATIONAL ANTI-ALZHEIMER'S DISEASE TREATMENTS
January 30, 2015 PHASE II TRIAL OF ANTICANCER AGENT LENVATINIB IN RENAL CELL CARCINOMA MEETS PRIMARY ENDPOINT
January 30, 2015 Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2015
January 26, 2015 EISAI AND AJINOMOTO PHARMACEUTICALS LAUNCH BRANCHED-CHAIN AMINO ACID FORMULA LIVAMIN® ORAL GRANULES IN THE PHILIPPINES
January 23, 2015 EISAI LISTED IN GLOBAL 100 SUSTAINABILITY INDEX FOR THIRD CONSECUTIVE YEAR
ONLY COMPANY FROM JAPAN INCLUDED IN 2015
January 5, 2015 PHASE III TRIAL OF ANTIEPILEPTIC DRUG PERAMPANEL AS ADJUNCTIVE THERAPY IN PATIENTS WITH REFRACTORY PARTIAL-ONSET SEIZURES CONDUCTED IN ASIA INCLUDING JAPAN AND CHINA MEETS PRIMARY ENDPOINT

Back to Top